Cristina Tassorelli Selected Research

Cristina Tassorelli Research Topics

Disease

99	Migraine Disorders (Migraine) 03/2024 - 10/2005
59	Pain (Aches) 01/2024 - 01/2003
37	Headache (Headaches) 01/2024 - 06/2006
24	Hyperalgesia 11/2023 - 08/2002
12	Stroke (Strokes) 01/2024 - 02/2010
12	Parkinson Disease (Parkinson's Disease) 10/2023 - 01/2004
9	Secondary Headache Disorders 01/2023 - 11/2010
8	Cognitive Dysfunction 01/2023 - 01/2019
8	Deglutition Disorders (Dysphagia) 12/2022 - 01/2017
8	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019 - 09/2007
7	Neuralgia (Stump Neuralgia) 11/2023 - 02/2015
7	Brain Ischemia (Cerebral Ischemia) 01/2021 - 09/2007
6	Epilepsy (Aura) 01/2023 - 10/2013
6	Ischemia 01/2015 - 01/2007
5	Cluster Headache (Cluster Headaches) 01/2023 - 08/2008
5	Ischemic Stroke 06/2021 - 01/2007
4	COVID-19 01/2023 - 01/2020
4	Chronic Pain 01/2019 - 08/2002
4	Migraine without Aura (Common Migraine) 01/2019 - 01/2002
4	Primary Headache Disorders 11/2018 - 04/2010
3	Polyneuropathies (Polyneuropathy) 01/2023 - 01/2021
3	Dementia (Dementias) 01/2023 - 01/2020
3	Inflammation (Inflammations) 07/2022 - 01/2015
3	Prescription Drug Overuse 01/2021 - 11/2018
3	Multiple Sclerosis 10/2019 - 01/2017
3	Neuroinflammatory Diseases 01/2018 - 07/2012
3	Reperfusion Injury 01/2018 - 02/2010
2	Constipation 02/2024 - 08/2012
2	Mental Disorders (Mental Disorder) 02/2024 - 01/2016
2	Trigeminal Neuralgia (Tic Douloureux) 11/2023 - 12/2017
2	Neurocognitive Disorders (Clerambault Syndrome) 01/2023 - 01/2021
2	Nausea 01/2023 - 11/2019

Drug/Important Bio-Agent (IBA)

31	Nitroglycerin (Dynamite)FDA LinkGeneric 06/2023 - 01/2003
19	Calcitonin Gene-Related PeptideIBA 03/2024 - 05/2015
19	EndocannabinoidsIBA 02/2024 - 09/2007
17	Formaldehyde (Formol)FDA Link 06/2023 - 01/2003
14	Type A Botulinum Toxins (Botox)FDA Link 01/2023 - 08/2011
12	Monoclonal AntibodiesIBA 03/2024 - 12/2020
10	anandamide (arachidonylethanolamide)IBA 11/2023 - 09/2007
10	CytokinesIBA 11/2023 - 01/2003
9	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2018
9	Tryptamines (Triptans)IBA 01/2021 - 02/2008
8	incobotulinumtoxinA FDA Link 01/2023 - 01/2017
8	Botulinum Toxins (Botulinum Toxin)IBA 12/2022 - 12/2006
7	Analgesics (Analgesic Drugs)IBA 01/2024 - 01/2003
7	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 11/2023 - 09/2007
7	Biomarkers (Surrogate Marker)IBA 03/2023 - 07/2012
7	Pain-FreeIBA 01/2021 - 01/2002
6	LipidsIBA 02/2024 - 07/2010
6	EnzymesIBA 11/2023 - 01/2003
6	Messenger RNA (mRNA)IBA 11/2023 - 01/2015
6	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2017 - 08/2002
5	CannabinoidsIBA 11/2023 - 09/2007
4	fremanezumabIBA 03/2024 - 11/2021
4	erenumabIBA 11/2023 - 10/2020
4	Estrogens (Estrogen)FDA Link 01/2022 - 09/2007
4	Hormones (Hormone)IBA 01/2022 - 09/2013
4	Glutamic Acid (Glutamate)FDA Link 07/2018 - 03/2006
3	atogepantIBA 02/2024 - 01/2022
3	URB937IBA 11/2023 - 01/2020
3	NeuropeptidesIBA 11/2023 - 07/2018
3	preemptIBA 01/2023 - 01/2022
3	eptinezumabIBA 01/2023 - 02/2022
3	galcanezumabIBA 01/2023 - 01/2021
3	lasmiditanIBA 01/2023 - 11/2019
3	Opioid Analgesics (Opioids)IBA 01/2023 - 10/2013
3	AnkyrinsIBA 11/2022 - 09/2017
3	Matrix Metalloproteinases (MMPs)IBA 10/2022 - 01/2015
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 01/2015
3	Peptides (Polypeptides)IBA 07/2022 - 05/2015
3	Dioctyl Sulfosuccinic Acid (DOSS)IBA 01/2022 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 11/2021 - 02/2011
3	Nitric Oxide DonorsIBA 01/2020 - 01/2007
3	Receptor for Advanced Glycation End ProductsIBA 04/2017 - 07/2012
3	ProstaglandinsIBA 01/2007 - 01/2003
2	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 02/2024 - 01/2022
2	rimegepant sulfateIBA 02/2024 - 01/2023
2	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2024 - 12/2016
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2024 - 01/2003
2	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 11/2023 - 01/2022
2	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2023 - 01/2016
2	Retinaldehyde (Retinal)IBA 01/2023 - 01/2009
2	Tissue Inhibitor of Metalloproteinase-1IBA 10/2022 - 10/2021
2	Metalloproteases (Metalloproteinases)IBA 10/2022 - 01/2015
2	Tissue Inhibitor of Metalloproteinase-2IBA 10/2022 - 10/2021
2	Substance PIBA 07/2022 - 09/2017
2	Interleukin-1beta (Interleukin 1 beta)IBA 07/2022 - 02/2010
2	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 07/2022 - 01/2020
2	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 07/2022 - 08/2012
2	mesoglycanIBA 03/2022 - 11/2021
2	palmidrolIBA 03/2022 - 01/2021

Therapy/Procedure

32	Therapeutics 03/2024 - 10/2005
12	Neurological Rehabilitation 01/2024 - 12/2015
8	Cognitive Training 01/2023 - 01/2019
8	Vagus Nerve Stimulation 10/2020 - 01/2018
6	Transcranial Direct Current Stimulation 01/2022 - 01/2019
4	Telerehabilitation 10/2023 - 01/2020
4	Aftercare (After-Treatment) 02/2022 - 01/2018
2	Analgesia 11/2023 - 01/2022
2	Deep Brain Stimulation 10/2023 - 11/2009